New Biocompatibility Standards: How to Vet Your Testing Partner

# New Biocompatibility Standards: A Guide to Vetting Your Testing Partner Selecting a biocompatibility testing laboratory is one of the most critical decisions a medical device manufacturer will make. With international consensus standards like the ISO 10993 series undergoing significant updates, the choice of a testing partner has evolved from a simple procurement task to a strategic regulatory decision. Regulators, including the FDA, are placing greater emphasis on a risk-based approach, focusing heavily on chemical characterization and toxicological risk assessment before any traditional biological tests are performed. This shift means that a laboratory’s role is no longer just to execute tests but to act as a strategic partner in developing a holistic Biological Evaluation Plan (BEP). Manufacturers must now look beyond basic accreditations and ask deeper, more probing questions to ensure their chosen lab can navigate the evolving landscape and produce data that will withstand regulatory scrutiny. A failure to properly vet a lab can lead to incomplete data, unexpected testing requirements, and significant delays in a product's path to market. ## Key Points * **Accreditation is the Starting Point, Not the Finish Line:** While ISO/IEC 17025 accreditation is essential, it only confirms a lab's quality management system for specific tests. It does not guarantee strategic expertise in modern, risk-based biocompatibility evaluation. * **Focus on Chemical Characterization Expertise:** A lab's ability to perform robust extractables and leachables (E&L) studies (as outlined in ISO 10993-18) is now paramount. This requires advanced analytical chemistry capabilities and toxicologists who can interpret the data. * **Demand a Toxicologist on the Team:** The interpretation of chemical characterization data requires a qualified toxicologist (as per ISO 10993-17) to assess risks and determine if further biological testing is necessary. Ask to see the credentials and experience of their toxicology team. * **Differentiate Test Execution from Strategic Planning:** A true partner will help develop the entire Biological Evaluation Plan (BEP), not just quote prices for individual tests. They should ask questions about your device's materials, manufacturing processes, and intended use to create a comprehensive, defensible strategy. * **Ask for Evidence of Proactive Adaptation:** A forward-looking lab should be able to provide tangible proof of how they have integrated new standards, such as updated report templates, revised SOPs for risk assessment, or anonymized case studies demonstrating their modern approach. * **Early Engagement is Key:** Involving your testing partner early in the device development process can prevent costly missteps. This is especially important before finalizing materials or manufacturing processes that could impact the biocompatibility profile. ## Understanding the Modern Biocompatibility Paradigm The philosophy behind biocompatibility evaluation has fundamentally shifted. Previously, the approach was often a checklist of *in vivo* and *in vitro* biological tests based on the device's contact type and duration. Today, the focus is on a comprehensive risk assessment process, as emphasized in FDA guidance and the ISO 10993 standards. This modern approach can be summarized as: 1. **Material and Process Characterization:** What is the device made of, and how is it manufactured, processed, and sterilized? 2. **Chemical Characterization:** What chemicals could potentially be released from the device during use? This is assessed through rigorous extractables and leachables testing. 3. **Toxicological Risk Assessment:** Are the identified chemicals present at levels that could pose a risk to patients? A toxicologist evaluates this risk. 4. **Targeted Biological Testing:** If the chemical and toxicological risk assessments cannot rule out all potential harms, then and only then is specific biological testing conducted to address the remaining questions. This places immense pressure on a testing lab's analytical chemistry and toxicology departments. A lab that is still primarily focused on selling a standard menu of biological tests may not be equipped to provide the strategic, chemistry-first approach that regulators now expect. ## A Framework for Vetting Your Biocompatibility Testing Partner To ensure you select a partner capable of meeting future regulatory expectations, use a structured vetting process that goes beyond surface-level qualifications. ### Tier 1: The Foundational Checklist (The "Must-Haves") This first step confirms the lab meets basic quality and regulatory requirements. * **Accreditation and Compliance:** * Is the lab ISO/IEC 17025 accredited for the specific tests you may need? Request a copy of their scope of accreditation. * Does the lab operate under Good Laboratory Practice (GLP) standards, as defined in regulations like **21 CFR** Part 58? This is critical for data intended for regulatory submissions. * **Experience and Reputation:** * How long has the lab been performing biocompatibility testing for medical devices? * Can they provide references or anonymized examples of successful submissions for devices similar to yours (e.g., in terms of class, materials, or clinical application)? * **Capacity and Turnaround Time:** * What is their current capacity for key tests like chemistry and cytotoxicity? * What are their stated versus actual average turnaround times? ### Tier 2: Assessing Technical and Strategic Depth This is where you differentiate a test executor from a strategic partner. **Probing Questions for the Chemistry Team:** * "Describe your laboratory's approach to designing an extraction study under ISO 10993-18. How do you justify solvent choice, extraction conditions, and time points for a novel device?" * "What is your Analytical Evaluation Threshold (AET)? How do you calculate and justify it for a specific device?" * "What analytical techniques (e.g., GC-MS, LC-MS, ICP-MS) do you use for screening, and what are their typical limits of detection?" * "How do you handle the identification of 'unknown' compounds found during chemical characterization?" **Probing Questions for the Toxicology Team:** * "Who on your staff performs the toxicological risk assessments? Can we review the CV of your lead toxicologist?" * "Describe your process for evaluating risk according to ISO 10993-17. How do you establish a Tolerable Intake (TI) for a chemical without existing toxicological data?" * "Can you provide an example (redacted) of a toxicological risk assessment report to demonstrate your methodology and reporting format?" * "How do you stay current with evolving regulatory interpretations of risk assessment, particularly from FDA and EU Notified Bodies?" **Probing Questions on Strategy and Planning:** * "Will you help us write our Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER)?" * "How do you approach a device made from a novel material with no history of medical use?" * "Describe a time you recommended *against* performing a biological test based on a favorable chemical risk assessment. What was the rationale and the outcome?" ### Scenario 1: Startup with a Novel Polymer-Coated Implant A small company is developing a long-term implantable sensor with a novel, drug-eluting polymer coating. Their biocompatibility profile is complex and high-risk. * **What to Scrutinize:** They need a high-touch, strategic partner. The lab's expertise in analytical chemistry and toxicology is paramount. They should prioritize a lab that can co-develop the entire BEP and has extensive experience with novel materials and combination products. * **Critical Questions:** "How would you design a study to characterize the degradation profile of our polymer over time? How will you assess the risk of both the polymer itself and the eluted drug? Can you help us structure this data for a Q-Submission to FDA?" ### Scenario 2: Large Company with a Line Extension An established manufacturer is launching a new version of a surgical instrument. It uses the same well-characterized stainless steel as their predicate device but has a minor change in geometry. * **What to Scrutinize:** Their primary need is efficiency, reliability, and clear documentation. While a risk-based approach is still required, the strategy is more straightforward. They need a lab that can efficiently perform a gap analysis against the predicate, justify a limited testing plan, and provide documentation quickly. * **Critical Questions:** "What is your standard process for documenting a biocompatibility rationale for a device with predicate history? Can your reports clearly justify why certain tests were omitted? What is your capacity for high-volume cytotoxicity and sensitization testing?" ## Strategic Considerations and the Role of Q-Submission Choosing the right testing partner is a critical component of your overall regulatory strategy. A strong lab partner will not only generate data but also help you present it within a compelling scientific narrative that is easy for regulators to review. For devices with novel materials, new manufacturing processes, or complex biocompatibility profiles, engaging the FDA early via the Q-Submission program is highly recommended. A well-prepared Q-Submission on biocompatibility should include a draft BEP and a clear rationale for your proposed testing strategy. Your testing partner can be invaluable in preparing this submission, ensuring the questions you ask the FDA are precise and that your proposed plan is based on sound scientific principles and current **FDA guidance**. A successful Q-Sub can provide invaluable agency feedback, de-risk your development program, and prevent significant delays during the final review. ## Finding and Comparing Biocompatibility Testing Services Providers Once you have a clear understanding of the technical and strategic capabilities you require, the next step is to identify and evaluate potential laboratories. Creating a formal request for proposal (RFP) that includes the probing questions listed above can help you systematically compare providers. Look for labs that provide detailed, thoughtful answers rather than generic sales material. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA references When developing a biocompatibility plan, sponsors should always refer to the latest versions of official standards and regulations. Key foundational documents include: * **FDA's Guidance on the Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process."** This is the primary document outlining FDA's thinking on the topic. * **The ISO 10993 series of standards.** This collection of over 20 standards provides detailed methodologies for everything from test selection to chemical characterization and animal welfare. * **21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies).** This regulation outlines the requirements for conducting nonclinical studies that support regulatory submissions. * **FDA's Q-Submission Program guidance.** This document explains the process for requesting feedback from the agency on your planned testing strategy before you conduct the tests. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*